Skip to main content

Table 2 Clinicopathologic characteristics of the 35 lung adenocarcinoma cases

From: MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

    MET gene FISH status  
    FISH-negative FISH-positive p-value
  Total % Total % Total %  
Variables 35 100 24 100 11a 100  
Age        
<65 13 37 9 38 4 36  
65 22 63 15 63 7 64 1.00
Gender        
Male 15 43 12 50 3 27  
Female 20 57 12 50 8 73 0.28
Smoking status        
Current and former smoker 14 40 10 42 4 36  
Never smoker 21 60 14 58 7 63 1.00
Stage        
III 4 11 3 13 1 9  
IV + Relapse 31 89 21 87 10 91 1.00
EGFR mutation subtype        
Exon19 deletion 25 71 19 79 6 55  
Exon21 L858R 10 29 5 21 5 46 0.23
Response to Gefitinib        
CR + PR 31 89 22 92 9 82  
SD + PD 4 11 2 8 2 18 0.57
  1. aHigh polysomy was observed in 10 patients (28.5%) and amplification was in 1 patients (2.9%) of 35 NSCLC patients.